TRex Bio, Inc. closed its IPO, raising approximately $116.7 million by offering 8,333,334 shares at $14 each.
Quiver AI Summary
TRex Bio, Inc. has successfully completed its initial public offering, selling 8,333,334 shares of common stock at $14.00 each, resulting in approximately $116.7 million in gross proceeds before expenses. The company's stock will be traded on the Nasdaq under the ticker symbol "TRXB." J.P. Morgan, Evercore ISI, Cantor, and Stifel are among the lead managers for the offering, which had its registration statement effective as of October 8, 2026. TRexBio focuses on tissue Treg biology to develop immunoregulatory medicines aimed at treating autoimmune and inflammatory diseases, leveraging its Deep Biology Platform for drug discovery. The company is headquartered in South San Francisco and is led by an experienced management team.
Potential Positives
- TRexBio successfully closed its initial public offering, raising approximately $116.7 million, which provides significant funding for its clinical-stage biotechnology initiatives.
- The company's common stock is now listed on the Nasdaq Global Select Market, enhancing its visibility and access to investors.
- TRexBio has established a strong leadership team, which is crucial for navigating the complexities of the biotechnology sector and driving the company's growth.
Potential Negatives
- All shares in the initial public offering were sold by TRexBio, which may indicate that the company does not have sufficient investor confidence to attract external investors.
- The initial public offering price of $14.00 per share could suggest weak demand if shares do not appreciate significantly post-IPO, reflecting negatively on market perception.
- The press release's lack of significant details about the company's financial health or future plans after the IPO may raise concerns among potential investors about transparency and strategic direction.
FAQ
What is TRex Bio, Inc.?
TRex Bio, Inc. is a clinical-stage biotechnology company focusing on tissue Treg biology for developing immunoregulatory medicines.
When did TRexBio complete its IPO?
TRexBio closed its initial public offering on October 13, 2026.
How many shares were offered in TRexBio's IPO?
TRexBio offered 8,333,334 shares of its common stock during the IPO.
What was the IPO price per share?
The initial public offering price for TRexBio's shares was $14.00 each.
Where can I find more information about TRexBio's IPO?
Information and copies of the prospectus are available through J.P. Morgan and Evercore Group.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TRXB Insider Trading Activity
$TRXB insiders have traded $TRXB stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $TRXB stock by insiders over the last 6 months:
- VI, LLC SVLSF has made 2 purchases buying 92,857 shares for an estimated $1,299,998 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Full Release
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, today announced the closing of its initial public offering of 8,333,334 shares of its common stock at the initial public offering price of $14.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, was approximately $116.7 million. All of the shares were sold by TRexBio. TRexBio’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol “TRXB”.
J.P. Morgan, Evercore ISI, Cantor, and Stifel are acting as lead book-running managers for the offering. Wedbush PacGrow is acting as book-running manager for the offering.
A registration statement (File No. 333-299018) relating to the shares sold in the offering has been filed with the U.S. Securities and Exchange Commission (“SEC”) and became effective on October 8, 2026. The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from: J.P. Morgan Securities LLC, Attention Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected]; and Evercore Group L.L.C., 55 East 52nd Street, 35th Floor, New York, New York 10055, Attention: Equity Capital Markets, or by email at [email protected], or by telephone at (888) 474-0200.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About TRexBio
TRexBio is a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio’s Deep Biology Platform decodes Treg functionality in human tissue, mapping key drivers of immune dysregulation and uncovering novel targets and insights that inform drug discovery and translational efforts. This platform has generated multiple therapeutic development candidates across TRexBio’s wholly owned pipeline and through collaborations with leading pharmaceutical partners. TRexBio is led by an experienced management team and headquartered in South San Francisco, California.
